Another Near Miss For Zynerba's Cannabidiol Gel
Executive Summary
Zynerba's gel formulation of cannabidiol has failed to hit the primary endpoint in a second Phase II study in as many weeks, but the company maintains that there is a way forward.
You may also be interested in...
Zynerba Sketches Phase III Plan For Cannabinoid Gel In Fragile X
Positive Phase II study of cannabinoid ZYN002 sends stock soaring, but the trial was very small with an open-label design, and response was mostly recorded by caregivers.
Commercial Capsules: BMS's Opdivo Knock; Novo Nordisk Vs Eli Lilly; Roivant Raises; Sun Plunges; Other R&D Stumbles
Bristol-Myers Squibb faces a second clinical disappointment with Opdivo/Yervoy, allowing Exelixis to take advantage; Novo Nordisk claims a victory over Eli Lilly in the GLP-1 space; Roivant Sciences closed a $1.1bn equity financing; India’s biggest drug firm, Sun Pharma, slid into the red; Regeneron drops out of RSV; and Zynerba's cannabidiol gel misses again. Commercial Capsules rounds up key commercial news reported recently by sister publication Scrip.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.